According to the Market Statsville Group (MSG), the global infliximab market size is expected to grow at a CAGR of 11.3% from 2023 to 2033.

The increasing prevalence of inflammatory diseases such as Crohn's disease and ulcerative colitis are major driving factors for the infliximab market. For instance, according to Crohn's and Colitis Foundation, approximately 3 million people in the United States live with inflammatory bowel disease (IBD), with approximately 70,000 new cases diagnosed yearly. This increasing prevalence of IBD is expected to drive demand for infliximab and other biologic medications. The development of new formulations of the medication, such as subcutaneous injections, which are more convenient for patients than intravenous infusions, are opportunities for the infliximab market. Additionally, expanding the market into emerging regions such as Asia Pacific and Latin America presents a significant opportunity for growth, as the prevalence of inflammatory diseases in these regions is increasing. The increasing use of infliximab for new indications such as psoriasis and psoriatic arthritis presents an opportunity to expand the market into new treatment areas.

Definition of the Global Infliximab Market

Infliximab is a biologic medication used to treat various inflammatory conditions, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis. It is a type of tumor necrosis factor (TNF) inhibitor that works by blocking TNF, a protein contributing to inflammation. Infliximab is typically administered through intravenous (IV) infusion, although some newer formulations of the medication can be given as subcutaneous injections. The medication is typically given in a healthcare setting, such as a hospital or infusion centre. Infliximab is a complex medication that is produced using biotechnology. It is manufactured using recombinant DNA technology, in which genes are inserted into cells to produce the medication. Owing to its complexity and difficulty manufacturing biologics, infliximab is typically more expensive than traditional small molecule drugs. Infliximab has been shown to be effective in treating various inflammatory conditions, and it has been used by millions of patients worldwide.

Request Sample Copy of this Report: https://www.marketstatsville.com/request-sample/infliximab-market?utm_source=free&utm_medium=harsh                         

Scope of the Global Infliximab Market

The study categorizes the infliximab market based on product type, indication, and distribution channel area at the regional and global levels.

By Product Type Outlook (Sales, USD Million, 2019-2033)

• Remsima
• Inflectra
• Other Biosimilars

By Indication Outlook (Sales, USD Million, 2019-2033)

• Crohn's Disease
• Ulcerative Colitis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Psoriatic Arthritis
• Plaque Psoriasis
• Others

By Distribution Channel Outlook (Sales, USD Million, 2019-2033)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region Outlook (Sales, USD Million, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA

Direct Purchase Report: https://www.marketstatsville.com/buy-now/infliximab-market?opt=3338&utm_source=free&utm_medium=harsh

Remsima segment accounts for the largest market share by product type

Based on the product type, the market is divided into remsima, inflectra, and other biosimilars. The remsima segment is expected to dominate the market share in 2022 in the global infliximab market. Remsima is manufactured by Celltrion and was the first infliximab biosimilar to receive approval in Europe. Remsima has been widely studied and has demonstrated similar safety and efficacy to the originator brand in clinical trials, which can help to build confidence among healthcare providers and patients.

North America is expected to witness the largest market share by Region

Based on the regions, the global infliximab market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. North America is projected to account for the highest market share in 2022, owing to the high prevalence of chronic inflammatory diseases such as Crohn's disease and rheumatoid arthritis in the region. The availability of advanced healthcare infrastructure and the presence of key players in the region also contribute to the growth of the infliximab market in North America. Moreover, favourable reimbursement policies in the region for biologics such as infliximab is further propelling the market growth. Additionally, the rising demand for biosimilar infliximab in North America is expected to drive the market growth in the region.

Competitvie Landscape: Global Infliximab Market

The infliximab market is a significant competitor, and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.

Major key players in the global infliximab market are:

• Amgen Inc.
• Pfizer Inc.
• Eli Lilly and Company
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Eisai Co., Ltd
• Allergan
• Teva Pharmaceutical Industries Ltd
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Endo International plc
• Sun Pharmaceutical Industries Ltd
• Mylan N.V.
• Apotex Inc.
• Biocad

Request For Report TOC: https://www.marketstatsville.com/table-of-content/infliximab-market

Recent Developments

• In February 2022, Biocon Biologics, a subsidiary of Biocon, has acquired Viatris' biosimilars franchise, providing them with a strong commercial engine in the developed markets of the U.S. and Europe. This acquisition is expected to accelerate Biocon Biologics' efforts to establish a strong global brand.
• In December 2020, Endo International plc acquired BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company. This acquisition will immediately boost the adjusted EBITDA and profitability profile of XIAFLEX and Qwo, which are two highly durable and differentiated products with significant long-term growth potential.
• In July 2020, Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) approval of Hulio (adalimumab-fkjp), a biosimilar to AbbVie's Humira (adalimumab), for treating a range of inflammatory conditions, including rheumatoid arthritis, juvenile idiopathic arthritis (4 years and older), psoriatic arthritis, adult Crohn's disease, ankylosing spondylitis, ulcerative colitis, and plaque psoriasis. The two offer Hulio in both prefilled syringe and auto-injector presentations.